ArticleJournal of stroke2017
Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study.
Article in Journal of stroke, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Stroke secondary to cancer-associated coagulopathy: a systematic review.Journal of neurology · 2026Pooled it
- Huisheng Oral Solution Adjunct With Platinum-Based Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review.Frontiers in pharmacology · 2020Pooled it
- Anticoagulation Treatment Response Among Phenotypic ESUS Clusters: Evidence From CASPR.Annals of clinical and translational neurology · 2026Article
- Nit2/ω-amidase as a potential non-invasive diagnostic marker for moyamoya disease.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Thromboelastography identifies preoperative hypercoagulability in surgical patients with high stroke risk scores: A cross-sectional study.The Journal of international medical research · 2026Article
- Article
- Article
- Comparison of Antiplatelets and Anticoagulants for Secondary Stroke Prevention in Ischemic Stroke Patients with Cancer: A Meta-Analysis.Asian journal of neurosurgery · 2026Review
- Tissue factor activity and 1-year mortality in patients with active cancer and acute ischemic stroke: findings from the SCAN study.Research and practice in thrombosis and haemostasis · 2026Article
- Predicting cancer aetiology in patients with stroke using brain imaging alone.BMJ neurology open · 2026Article
- Trousseau syndrome presenting with recurrent multi-territory infarctions: a case report of two patients highlighting divergent outcomes and dynamic hypercoagulability under direct oral anticoagulants and low-molecular-weight heparin.Frontiers in cardiovascular medicine · 2026Article
- Presumptive Ewing Sarcoma of the Jejunum Presenting with Metastatic Disease: A Case Report and Focused Narrative Review.International medical case reports journal · 2026Article
- Atrial fibrillation and ischemic stroke in cancer: the latest scientific evidence, current management, and future directions.Journal of thrombosis and thrombolysis · 2025Review
- Development and validation of a risk assessment tool for ischemic stroke in cancer patients.Scientific reports · 2025Article
- Cerebrovascular and Peripheral Vascular Complications in Cancer Patients.Current neurology and neuroscience reports · 2025Review
- Anticoagulation Failure in Stroke: Causes, Risk Factors, and Treatment.Journal of stroke · 2025Review
- Cryptogenic embolic stroke and cancer.Frontiers in neurology · 2025Review
- Anticoagulant versus antiplatelet treatment for secondary stroke prevention in patients with active cancer.Frontiers in neurology · 2025Article
- Editorial: Cryptogenic ischemic stroke.Frontiers in neurology · 2025Article
- Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposePatients with active cancer are at an increased risk for stroke. Hypercoagulability plays an important role in cancer-related stroke. We aimed to test whether 1) hypercoagulability is a predictor of survival, and 2) correction of the hypercoagulable state leads to better survival in patients with stroke and active cancer.
methodsWe recruited consecutive patients with acute ischemic stroke and active systemic cancer between January 2006 and July 2015. Hypercoagulability was assessed using plasma D-dimer levels before and after 7 days of anticoagulation treatment. The study outcomes included overall and 1-year survival. Plasma D-dimer levels before and after treatment were tested in univariate and multivariate Cox regression models. We controlled for systemic metastasis, stroke mechanism, age, stroke severity, primary cancer type, histology, and atrial fibrillation using the forward stepwise method.
resultsA total of 268 patients were included in the analysis. Patients with high (3rd-4th quartiles) pre-treatment plasma D-dimer levels showed decreased overall and 1-year survival (adjusted HR, 2.19 [95% CI, 1.46-3.31] and 2.70 [1.68-4.35], respectively). After anticoagulation treatment, post-treatment D-dimer level was significantly reduced and independently associated with poor 1-year survival (adjusted HR, 1.03 [95% CI, 1.01-1.05] per 1 μg/mL increase,
conclusionsHypercoagulability is associated with poor survival after stroke in patients with active cancer. Effective correction of hypercoagulability may play a protective role for survival in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.